{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:42:04Z","timestamp":1776080524623,"version":"3.50.1"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100011684","name":"Crohn's and Colitis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011684","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biomarkers Consortium of the Foundation"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite major advances in the inflammatory bowel diseases field, biomarkers to enable personalized and effective management are inadequate. Disease course and treatment response are highly variable, with some patients experiencing mild disease progression, whereas other patients experience severe or complicated disease. Periodic endoscopy is performed to assess disease activity; as a result, it takes months to ascertain whether a treatment is having a positive impact on disease progression. Minimally invasive biomarkers for prognosis of disease course, prediction of treatment response, monitoring of disease activity, and accurate diagnosis based on improved disease phenotyping and classification could improve outcomes and accelerate the development of novel therapeutics. Rapidly developing technologies have great potential in this regard; however, the discovery, validation, and qualification of biomarkers will require partnerships including academia, industry, funders, and regulators. The Crohn\u2019s &amp; Colitis Foundation launched the IBD Biomarker Summit to bring together key stakeholders to identify and prioritize critical unmet needs; prioritize promising technologies and consortium approaches to address these needs; and propose harmonization approaches to improve comparability of data across studies. Here, we summarize the outcomes of the 2018 and 2019 meetings, including consensus-based unmet needs in the clinical and drug development context. We highlight ongoing consortium efforts and promising technologies with the potential to address these needs in the near term. Finally, we summarize actionable recommendations for harmonization, including data collection tools for improved consistency in disease phenotyping; standardization of informed consenting; and development of guidelines for sample management and assay validation. Taken together, these outcomes demonstrate that there is an exceptional alignment of priorities across stakeholders for a coordinated effort to address unmet needs of patients with inflammatory bowel diseases through biomarker science.<\/jats:p>","DOI":"10.1093\/ibd\/izaa210","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T07:56:59Z","timestamp":1597823819000},"page":"1451-1462","source":"Crossref","is-referenced-by-count":22,"title":["Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases"],"prefix":"10.1093","volume":"26","author":[{"given":"Gerard","family":"Honig","sequence":"first","affiliation":[{"name":"Crohn\u2019s & Colitis Foundation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caren","family":"Heller","sequence":"additional","affiliation":[{"name":"Crohn\u2019s & Colitis Foundation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Hurtado-Lorenzo","sequence":"additional","affiliation":[{"name":"Crohn\u2019s & Colitis Foundation"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,19]]},"reference":[{"key":"2022092121260439800_CIT0001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn\u2019s disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"2022092121260439800_CIT0002","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1093\/ibd\/izz078","article-title":"Challenges in IBD research: precision medicine","volume":"25","author":"Denson","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121260439800_CIT0003","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.gastro.2016.09.046","article-title":"Management strategies to improve outcomes of patients with inflammatory bowel diseases","volume":"152","author":"Colombel","year":"2017","journal-title":"Gastroenterology."},{"key":"2022092121260439800_CIT0004","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.cgh.2007.09.002","article-title":"Clinical course in Crohn\u2019s disease: results of a Norwegian population-based ten-year follow-up study","volume":"5","author":"Solberg","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092121260439800_CIT0005","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/apt.14373","article-title":"Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index","volume":"47","author":"Lo","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092121260439800_CIT0006","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00000658-200103000-00007","article-title":"Preoperative characteristics and postoperative behavior of bowel wall on risk of recurrence after conservative surgery in Crohn\u2019s disease: a prospective study","volume":"233","author":"Maconi","year":"2001","journal-title":"Ann Surg."},{"key":"2022092121260439800_CIT0007","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet."},{"key":"2022092121260439800_CIT0008","first-page":"400","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis."},{"key":"2022092121260439800_CIT0009","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/cpt.1362","article-title":"The Foundation for the National Institutes of Health Biomarkers Consortium: past accomplishments and new strategic direction","volume":"105","author":"Menetski","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"2022092121260439800_CIT0010","volume-title":"FDA-NIH Biomarker Working Group BEST (Biomarkers, EndpointS, and other Tools) Resource","year":"2016"},{"key":"2022092121260439800_CIT0011","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/ibd\/izz076","article-title":"Challenges in IBD research: environmental triggers","volume":"25","author":"Ho","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121260439800_CIT0012","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4599","article-title":"What evidence do we need for biomarker qualification?","volume":"9","author":"Leptak","year":"2017","journal-title":"Sci Transl Med."},{"key":"2022092121260439800_CIT0013","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/gutjnl-2019-318343","article-title":"A blood-based prognostic biomarker in IBD","volume":"68","author":"Biasci","year":"2019","journal-title":"Gut."},{"key":"2022092121260439800_CIT0014","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1172\/JCI59255","article-title":"Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis","volume":"121","author":"Lee","year":"2011","journal-title":"J Clin Invest."},{"key":"2022092121260439800_CIT0015","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1053\/j.gastro.2018.07.039","article-title":"Multiomics analyses to deliver the most effective treatment to every patient with inflammatory bowel disease","volume":"155","author":"Weersma","year":"2018","journal-title":"Gastroenterology."},{"key":"2022092121260439800_CIT0016","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1053\/j.gastro.2019.10.034","article-title":"Development and validation of a test to monitor endoscopic activity in patients with Crohn\u2019s disease based on serum levels of proteins","volume":"158","author":"D\u2019Haens","year":"2020","journal-title":"Gastroenterology."},{"key":"2022092121260439800_CIT0017","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/ecco-jcc\/jjz125","article-title":"The ulcerative colitis response index for detection of mucosal healing in patients treated with anti-tumour necrosis factor","volume":"14","author":"de Bruyn","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2022092121260439800_CIT0018","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/cpt.1744","article-title":"Beyond the randomized clinical trial: innovative data science to close the pediatric evidence gap","volume":"107","author":"Goulooze","year":"2020","journal-title":"Clin Pharmacol Ther."},{"key":"2022092121260439800_CIT0019","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.acra.2017.09.010","article-title":"Essentials of statistical methods for assessing reliability and agreement in quantitative imaging","volume":"25","author":"Anvari","year":"2018","journal-title":"Acad Radiol."},{"key":"2022092121260439800_CIT0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1602\/neurorx.1.2.182","article-title":"Biomarkers: potential uses and limitations","volume":"1","author":"Mayeux","year":"2004","journal-title":"NeuroRx."},{"key":"2022092121260439800_CIT0021","volume-title":"Scientific and Regulatory Considerations for the Analytical Validation of Assays Used in the Qualification of Biomarkers in Biological Matrices","author":"Biomarker Assay Collaborative Evidentiary Considerations Writing Group.","year":"2019"},{"key":"2022092121260439800_CIT0022","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1053\/j.gastro.2019.06.018","article-title":"Approaches to integrating biomarkers into clinical trials and care pathways as targets for the treatment of inflammatory bowel diseases","volume":"157","author":"Dulai","year":"2019","journal-title":"Gastroenterology."},{"key":"2022092121260439800_CIT0023","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1158\/1078-0432.CCR-13-2961","article-title":"Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer","volume":"20","author":"Parkinson","year":"2014","journal-title":"Clin Cancer Res."},{"key":"2022092121260439800_CIT0024"},{"key":"2022092121260439800_CIT0025","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1148\/radiol.10100800","article-title":"Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities","volume":"259","author":"Buckler","year":"2011","journal-title":"Radiology."},{"key":"2022092121260439800_CIT0026"},{"key":"2022092121260439800_CIT0027"},{"key":"2022092121260439800_CIT0028","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/ibd.22839","article-title":"Ulcerative colitis as a progressive disease: the forgotten evidence","volume":"18","author":"Torres","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121260439800_CIT0029","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(17)30317-3","article-title":"Prediction of complicated disease course for children newly diagnosed with Crohn\u2019s disease: a multicentre inception cohort study","volume":"389","author":"Kugathasan","year":"2017","journal-title":"Lancet."},{"key":"2022092121260439800_CIT0030","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut."},{"key":"2022092121260439800_CIT0031"},{"key":"2022092121260439800_CIT0032","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/ibd.20892","article-title":"Phenotypic associations of Crohn\u2019s disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort","volume":"15","author":"Schoepfer","year":"2009","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121260439800_CIT0033","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1053\/j.gastro.2005.03.046","article-title":"Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn\u2019s disease","volume":"128","author":"Targan","year":"2005","journal-title":"Gastroenterology."},{"key":"2022092121260439800_CIT0034","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00054725-200108000-00003","article-title":"Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn\u2019s disease","volume":"7","author":"Sandborn","year":"2001","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121260439800_CIT0035","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1053\/j.gastro.2008.02.083","article-title":"Multigene analysis can discriminate between ulcerative colitis, Crohn\u2019s disease, and irritable bowel syndrome","volume":"134","author":"von Stein","year":"2008","journal-title":"Gastroenterology."},{"key":"2022092121260439800_CIT0036","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/apt.13641","article-title":"Serologic microbial associated markers can predict Crohn\u2019s disease behaviour years before disease diagnosis","volume":"43","author":"Choung","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092121260439800_CIT0037","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","article-title":"Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn\u2019s disease","volume":"138","author":"Baert","year":"2010","journal-title":"Gastroenterology."},{"key":"2022092121260439800_CIT0038","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/MIB.0000000000000341","article-title":"Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission","volume":"21","author":"Falvey","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121260439800_CIT0039","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/ibd.21445","article-title":"Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity","volume":"17","author":"Regueiro","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121260439800_CIT0040","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","article-title":"Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis","volume":"14","author":"Shah","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092121260439800_CIT0041","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/ibd\/izz085","article-title":"Challenges in IBD research: pragmatic clinical research","volume":"25","author":"Scott","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121260439800_CIT0042","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.cgh.2019.12.014","article-title":"Systematic review and external validation of prediction models based on symptoms and biomarkers for identifying endoscopic activity in Crohn\u2019s disease","volume":"18","author":"Brand","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092121260439800_CIT0043","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MPG.0000000000001227","article-title":"Which PCDAI version best reflects intestinal inflammation in pediatric Crohn disease?","volume":"64","author":"Turner","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"2022092121260439800_CIT0044"},{"key":"2022092121260439800_CIT0045","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.cgh.2018.02.051","article-title":"Heterogeneity in definitions of efficacy and safety endpoints for clinical trials of Crohn\u2019s disease: a systematic review","volume":"16","author":"Ma","year":"2018","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092121260439800_CIT0046","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cgh.2019.11.052","article-title":"Use of cross-sectional imaging for tight monitoring of inflammatory bowel diseases","volume":"18","author":"Allocca","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092121260439800_CIT0047","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/apt.15250","article-title":"Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn\u2019s disease","volume":"49","author":"Novak","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092121260439800_CIT0048","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/gutjnl-2018-318137","article-title":"Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity","volume":"69","author":"Harpaz","year":"2020","journal-title":"Gut."},{"key":"2022092121260439800_CIT0049","first-page":"CD011450","article-title":"Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis","volume":"1","author":"Mohammed Vashist","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"2022092121260439800_CIT0050","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaa110","article-title":"ECCO position paper: harmonisation of the approach to ulcerative colitis histopathology","author":"Magro","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2022092121260439800_CIT0051","doi-asserted-by":"crossref","first-page":"101601","DOI":"10.1016\/j.bpg.2019.02.003","article-title":"What is the role of histopathology in the evaluation of disease activity in Crohn\u2019s disease?","volume":"38-39","author":"Pai","year":"2019","journal-title":"Best Pract Res Clin Gastroenterol."},{"key":"2022092121260439800_CIT0052","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.giec.2019.02.010","article-title":"The role of histology in determining disease activity, treatment, and prognosis: are we there yet?","volume":"29","author":"Salem","year":"2019","journal-title":"Gastrointest Endosc Clin N Am."},{"key":"2022092121260439800_CIT0053","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.cgh.2018.03.034","article-title":"Is the objective of treatment for Crohn\u2019s disease mucosal or transmural healing?","volume":"16","author":"Pan\u00e9s","year":"2018","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092121260439800_CIT0054","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1136\/gutjnl-2018-318081","article-title":"Assessment of Crohn\u2019s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review","volume":"68","author":"Bettenworth","year":"2019","journal-title":"Gut."},{"key":"2022092121260439800_CIT0055","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5217\/ir.2018.00114","article-title":"Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn\u2019s disease?: a systematic review","volume":"17","author":"Simon","year":"2019","journal-title":"Intest Res."},{"key":"2022092121260439800_CIT0056","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izaa025","article-title":"Association of biomarker cutoffs and endoscopic outcomes in crohn\u2019s disease: a Post Hoc analysis from the CALM study","author":"Reinisch","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121260439800_CIT0057","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/MIB.0000000000000296","article-title":"Serum C-reactive protein and CRP genotype in pediatric inflammatory bowel disease: influence on phenotype, natural history, and response to therapy","volume":"21","author":"Henderson","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121260439800_CIT0058","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ajhg.2019.12.002","article-title":"Allelic heterogeneity at the CRP locus identified by whole-genome sequencing in multi-ancestry cohorts","volume":"106","author":"Raffield","year":"2020","journal-title":"Am J Hum Genet."},{"key":"2022092121260439800_CIT0059","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.fpc.0000182776.57437.d8","article-title":"No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn\u2019s disease","volume":"16","author":"Willot","year":"2006","journal-title":"Pharmacogenet Genomics."},{"key":"2022092121260439800_CIT0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology."},{"key":"2022092121260439800_CIT0061","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fmed.2019.00279","article-title":"Can We predict the toxicity and response to thiopurines in inflammatory bowel diseases?","volume":"6","author":"Luber","year":"2019","journal-title":"Front Med (Lausanne)."},{"key":"2022092121260439800_CIT0062","doi-asserted-by":"crossref","first-page":"e0223832","DOI":"10.1371\/journal.pone.0223832","article-title":"Diagnostic test evaluation methodology: a systematic review of methods employed to evaluate diagnostic tests in the absence of gold standard - an update","volume":"14","author":"Umemneku Chikere","year":"2019","journal-title":"PLoS One."},{"key":"2022092121260439800_CIT0063","doi-asserted-by":"crossref","first-page":"e193963","DOI":"10.1001\/jamanetworkopen.2019.3963","article-title":"Performance of a deep learning model vs human reviewers in grading endoscopic disease severity of patients with ulcerative colitis","volume":"2","author":"Stidham","year":"2019","journal-title":"JAMA Netw Open."},{"key":"2022092121260439800_CIT0064","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1053\/j.gastro.2020.02.012","article-title":"Development and validation of a deep neural network for accurate evaluation of endoscopic images from patients with ulcerative colitis","volume":"158","author":"Takenaka","year":"2020","journal-title":"Gastroenterology."},{"key":"2022092121260439800_CIT0065"},{"key":"2022092121260439800_CIT0066","doi-asserted-by":"crossref","first-page":"843","DOI":"10.14309\/ajg.0000000000000556","article-title":"Independent blinded validation of a tissue systems pathology test to predict progression in patients with Barrett\u2019s esophagus","volume":"115","author":"Davison","year":"2020","journal-title":"Am J Gastroenterol."},{"key":"2022092121260439800_CIT0067","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izaa211","article-title":"Potential for standardization and automation for pathology and endoscopy in inflammatory bowel diseases","volume-title":"Inflamm Bowel Dis.","author":"Syed","year":"2020"},{"key":"2022092121260439800_CIT0068","doi-asserted-by":"crossref","first-page":"e026767","DOI":"10.1136\/bmjopen-2018-026767","article-title":"Predicting outcomes for Crohn\u2019s disease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial","volume":"8","author":"Parkes","year":"2018","journal-title":"BMJ Open."},{"key":"2022092121260439800_CIT0069","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izaa217","article-title":"Tissue-based gene expression as potential biomarkers for IBD course","volume-title":"Inflamm Bowel Dis.","author":"Haberman","year":"2020"},{"key":"2022092121260439800_CIT0070","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1093\/ibd\/izz077","article-title":"Challenges in IBD research: novel technologies","volume":"25","author":"Dhyani","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121260439800_CIT0071","article-title":"Preferences of adult patients with inflammatory bowel disease for attributes of clinical trials: evidence from a choice-based conjoint analysis","volume":"2","author":"Wood","year":"2019","journal-title":"J Crohns Colitis."},{"key":"2022092121260439800_CIT0072","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/MIB.0000000000000062","article-title":"Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis","volume":"20","author":"Arai","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121260439800_CIT0073","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/MPG.0000000000001477","article-title":"Prostaglandin E-major urinary metabolite as a biomarker for pediatric ulcerative colitis activity","volume":"64","author":"Hagiwara","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"2022092121260439800_CIT0074","article-title":"Biomarkers of Crohn\u2019s disease to support the development of new therapeutic interventions","volume-title":"Inflamm Bowel Dis.","author":"Aubrecht","year":"2020"},{"key":"2022092121260439800_CIT0075","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izaa071","article-title":"Microbiome-based biomarkers for IBD","author":"Ananthakrishnan","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121260439800_CIT0076","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izaa218","article-title":"Clinical-stage approaches for imaging chronic inflammation and fibrosis in Crohn\u2019s disease.","volume-title":"Inflamm Bowel Dis.","author":"Greer","year":"2020"},{"key":"2022092121260439800_CIT0077","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/apt.14853","article-title":"An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn\u2019s disease","volume":"48","author":"Rieder","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092121260439800_CIT0078","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izaa213","article-title":"Toward molecular imaging of intestinal pathology.","volume-title":"Inflamm Bowel Dis.","author":"Le Fur","year":"2020"},{"key":"2022092121260439800_CIT0079","first-page":"30","article-title":"The International Consortium for Harmonization of Clinical Laboratory Results (ICHCLR) - a pathway for harmonization","volume":"27","author":"Myers","year":"2016","journal-title":"Ejifcc."},{"key":"2022092121260439800_CIT0080","year":"2020"},{"key":"2022092121260439800_CIT0081","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1056\/NEJMp1401444","article-title":"Fostering responsible data sharing through standards","volume":"370","author":"Kush","year":"2014","journal-title":"N Engl J Med."},{"key":"2022092121260439800_CIT0082"},{"key":"2022092121260439800_CIT0083","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1053\/j.gastro.2019.03.051","article-title":"Development and validation of a simplified magnetic resonance index of activity for Crohn\u2019s disease","volume":"157","author":"Ord\u00e1s","year":"2019","journal-title":"Gastroenterology."},{"key":"2022092121260439800_CIT0084","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc."},{"key":"2022092121260439800_CIT0085","volume-title":"Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk","author":"Institute of M","year":"2015"},{"key":"2022092121260439800_CIT0086","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.trci.2017.08.003","article-title":"Concise informed consent to increase data and biospecimen access may accelerate innovative Alzheimer\u2019s disease treatments","volume":"3","author":"Hake","year":"2017","journal-title":"Alzheimers Dement (N Y)."},{"key":"2022092121260439800_CIT0087","doi-asserted-by":"crossref","first-page":"e000147","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","volume":"8","author":"Merino","year":"2020","journal-title":"J Immunother Cancer."},{"key":"2022092121260439800_CIT0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2020.01.023","article-title":"Harmonization and standardization of panel-based tumor mutational burden measurement: real-world results and recommendations of the quality in pathology study","author":"Stenzinger","year":"2020","journal-title":"J Thorac Oncol."},{"key":"2022092121260439800_CIT0089","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1002\/jmri.26598","article-title":"Recommendations toward standards for quantitative MRI (qMRI) and outstanding needs","volume":"49","author":"Keenan","year":"2019","journal-title":"J Magn Reson Imaging."},{"key":"2022092121260439800_CIT0090","doi-asserted-by":"crossref","first-page":"180268","DOI":"10.1038\/sdata.2018.268","article-title":"Overview and experience of the YODA Project with clinical trial data sharing after 5 years","volume":"5","author":"Ross","year":"2018","journal-title":"Sci Data."},{"key":"2022092121260439800_CIT0091","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMp1605348","article-title":"A Global, neutral platform for sharing trial data","volume":"374","author":"Bierer","year":"2016","journal-title":"N Engl J Med."},{"key":"2022092121260439800_CIT0092","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cgh.2012.02.004","article-title":"Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population","volume":"10","author":"Ha","year":"2012","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/10\/1451\/45965380\/ibd_26_10_1451.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/10\/1451\/45965380\/ibd_26_10_1451.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T21:35:25Z","timestamp":1663796125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/26\/10\/1451\/5894181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":92,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,8,19]]},"published-print":{"date-parts":[[2020,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaa210","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,8,19]]}}}